2013-11-15T10:30:23-06:00 2012-12-31 KPMG LLP 60 South Street Boston MA 02111 990 2012-01-01 010211513 THE JACKSON LABORATORY % LINDA A JENSEN JACK 2072886000 600 MAIN STREET Suite BAR HARBOR ME 04609 LINDA JENSEN 2013-11-13 6179881000 2012 2016-02-25 16:41:14Z LINDA A JENSEN 600 Main Street BAR HARBOR ME 04609 251129254 false X WWW.JAX.ORG X 1929 ME WE DISCOVER PRECISE GENOMIC SOLUTIONS FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. 22 20 1661 156 3588 -12313 41644804 67271113 90488058 159830571 3551199 2796712 680802 1181585 136364863 231079981 0 0 0 0 59770920 111935295 0 0 2402953 50881545 91016891 110652465 202952186 25712398 28127795 445421776 527038278 128042389 176017760 317379387 351020518 X WE DISCOVER PRECISE GENOMIC SOLUTIONS FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. false false 98534564 158899432 DEVELOP AND PROVIDE GENETIC RESOURCES - PLEASE SEE SCHEDULE O FOR DETAIL. 71261553 450851 BIOMEDICAL RESEARCH - PLEASE SEE SCHEDULE O FOR DETAIL. 2583927 480288 EDUCATION AND TRAINING - PLEASE SEE SCHEDULE O FOR DETAIL. 172380044 true true false true false false false false false true true true false true true true true false false true true false false true true false false false false true true true false false false false false false false true true true false false false false false false false false true 166 0 true 1661 true true true false false false false true true false false false false X 22 20 true false false false false false false true true false false true true true true true true true true false CA CT FL ME MA NY PA X X X LINDA A JENSEN 2072886108 600 MAIN STREET BAR HARBOR ME 04609 EDISON T LIU MD 40.0 X X 786307 0 122116 CHARLES E HEWETT PHD 40.0 X X 655809 0 250209 DAVID R CABOT 1.0 X 0 0 0 KATHLEEN A CORBET 1.0 X 0 0 0 LOUIS J D'AMBROSIO 1.0 X 0 0 0 ROSS E DWORMAN 1.0 X 0 0 0 DAVID D ELLIMAN 1.0 X 0 0 0 JAMES J GALLOGLY 1.0 X X 0 0 0 RICHARD S GURIN 1.0 X 0 0 0 LEO A HOLT 1.0 X 0 0 0 WESLIE R JANEWAY 1.0 X 0 0 0 RICHARD S LANNAMANN 1.0 X 0 0 0 SAM R LITTLE 1.0 X 0 0 0 DAVID J ROUX 1.0 X 0 0 0 TOM S VOLPE 1.0 X 0 0 0 PETER GERRITY 1.0 X X 0 0 0 EDWARD L SAMEK 1.0 X X 0 0 0 DAVID BALTIMORE PHD 1.0 X 0 0 0 JEFFREY M DUNN MD 1.0 X 0 0 0 ANTHONY B EVNIN PHD 1.0 X 0 0 0 WILLIAM S HARWOOD ESQ 1.0 X 0 0 0 TOM P MANIATIS PHD 1.0 X 0 0 0 NEAL B MILCH JD 1.0 X 0 0 0 CHARLES M RICE PHD 1.0 X 0 0 0 SHIRLEY M TILGHMAN PHD 1.0 X 0 0 0 DAVID VALLE 1.0 X 0 0 0 JANA ROBINSON 40.0 X 50224 0 29800 JOSEPH VETELINO 40.0 X 104861 0 34862 MICHAEL HYDE 40.0 X 313339 0 62513 LINDA A JENSEN MS 40.0 X 312181 0 57280 KATHY L VANDEGRIFT 40.0 X 267166 0 45172 LEAH RAE B DONAHUE PHD 40.0 X 218305 0 47352 AUROBINDO NAIR PHD 40.0 X 312870 0 55288 ROBERT BRAUN PHD 40.0 X 334531 0 36110 MICHAEL WATERS 40.0 X 212115 0 49493 LINDA WATERMAN DVM 40.0 X 236243 0 25763 JANAN T EPPIG PHD 40.0 X 226593 0 41490 GARY A CHURCHILL PHD 40.0 X 210903 0 50535 JOANNE RUH 40.0 X 321034 0 25704 4562481 0 933687 115 false true false COLUMBUS IT PARTNERS 750 WASHINGTON BOULEVARD 5TH FLOOR STAMFORD CT 06901 IT CONSULTING 1419445 VELOCITY TECHNOLOGY SOLUTIONS INC 850 THIRD AVENUE NEW YORK NY 10022 IT CONSULTING 655781 CENTERBROOK ARCH AND PLANNERS LLP 67 MAIN STREET CENTERBROOK CT 06409 ARCH/CONTR MGMT 3960962 BVH INTEGRATED SERVICES INC 50 GRIFFIN ROAD S BLOOMFIELD CT 06002 ARCH ENGINEERING 1590259 HURON CONSULTING 550 W VAN BUREN STREET CHICAGO IL 60607 IT CONSULTING 928983 21 172222 57810755 9288136 163086 67271113 GENETIC RESOURCES 541710 158899432 158899432 TRAINING & EDUCATION 541710 480288 480288 RESEARCH 541710 450851 450851 159830571 1809695 3588 1806107 0 1082097 1082097 0 0 0 20880369 29843 19911883 11312 968486 18531 987017 987017 6888 172222 126078 -119190 -119190 0 0 OTHER REVENUE 900099 218678 218678 218678 231079981 160049249 3588 3756031 0 0 0 0 4464193 445606 4018587 0 80595983 67585995 11841782 1168206 6387713 5811292 475444 100977 14460966 12823631 1411728 225607 6026440 5070120 868684 87636 0 1274979 743755 530713 511 343044 70000 273044 56165 56165 0 200000 200000 5123310 2837244 2038293 247773 696848 639774 57074 2163817 1725776 343496 94545 3060618 2520973 497323 42322 95642 85642 10000 10795207 9471700 1291266 32241 4264883 3421932 579434 263517 0 406379 332801 69534 4044 3361259 3342313 18946 0 19335692 17485490 1770315 79887 1347178 1226634 115339 5205 OTHER SERVICES 1327369 1144375 179109 3885 STIPENDS 518010 517610 400 SUPPLIES 31580509 30140328 1401979 38202 EQUIPMENT RENTAL 274664 208594 58615 7455 4791318 4728459 61919 940 202952186 172380044 28169189 2402953 X 25000 25000 112670128 127411597 7585709 7608605 15116879 16269357 0 0 0 0 1400000 1400000 1781697 2113025 2944913 3745110 446277712 200693511 216643844 245584201 43862800 50547308 36978265 40207968 0 0 0 0 6412541 32126107 445421776 527038278 25314041 35361286 0 0 6367013 8529837 77905017 109371484 0 0 0 0 0 5262000 0 0 18456318 17493153 128042389 176017760 X 277744544 310202312 31242332 32170686 8392511 8647520 317379387 351020518 445421776 527038278 X 28127795 7481727 -1968391 X true X true X true true true X 66396577 69040663 73823292 41644804 67271113 318176449 0 0 66396577 69040663 73823292 41644804 67271113 318176449 0 318176449 4253688 3370975 2954194 2311932 2888204 15778993 0 21308 48973 33525 3588 107394 0 334062836 622923873 0.95244 0.94740 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false true 38698 false 38698 false LOBBYING ACTIVITY BY NON-ELECTING 501(C)(3) ORGANIZATION PART II-B, LINE 1G ADVOCACY ACTIVITIES IN MAINE AND CONNECTICUT ARE UNDERTAKEN BY THE JACKSON LABORATORY. MAINE ACTIVITIES ARE UNDERTAKEN BY THE DIRECTOR, OFFICE OF GOVERNMENTAL RELATIONS AT THE JACKSON LABORATORY, AND CONNECTICUT ACTIVITIES ARE UNDERTAKEN BY THE VICE PRESIDENT OF EXTERNAL AFFAIRS. THE TOTAL LOBBYING EXPENSE FOR THE YEAR ENDED DECEMBER 31, 2012 WAS $38,698, WHICH WAS AN ALLOCATION OF EMPLOYEE COMPENSATION FOR LOBBYING ACTIVITIES. THERE WERE NO OUTSIDE LOBBYING FIRMS OR GROUPS ENGAGED DURING THIS PERIOD. 80841065 1280959 9091700 458448 90755276 87452850 74725 -5827854 858656 80841065 74765000 2345649 10790669 448468 87452850 58922000 6051000 10277000 485000 74765000 80042000 76000 -20682000 514000 58922000 0.60000 0.09000 0.31000 false false 0 5642031 5642031 0 313744347 135618343 178126004 0 97886772 65075168 32811604 0 29004562 0 29004562 245584201 US EQUITY 9426445 F INTERNATIONAL EQUITY 14958370 F ALTERNATIVE 15823153 F 40207968 CERTIFICATES OF DEPOSITS 780754 ACCOUNTS RECEIVABLE - OTHER 1411645 OTHER 370466 EMPLOYEE BENEFIT ASSETS 3534024 ACCRUED INTEREST RECEIVABLE 135383 Cash Held by Trustee 25893835 32126107 0 RETIREMENT PLAN OBLIGATIONS 8496564 INTEREST RATE SWAP 8996589 17493153 X 236467262 7481727 -1968391 5513336 230953926 252133 -126078 126055 231079981 202826131 126078 126078 202700053 252133 252133 202952186 ENDOWMENT FUNDS PART V, LINE 4 THE INVESTMENT AND SPENDING POLICIES FOR THE ENDOWMENT ASSETS HAVE BEEN ESTABLISHED TO PROVIDE A PREDICTABLE STREAM OF FUNDING FOR THE PROGRAMS SUPPORTED BY ENDOWMENT INCOME, WHILE SEEKING TO MAINTAIN THE PURCHASING POWER OF THE ENDOWMENT ASSETS. IN ADDITION, WHEN CONSIDERING THE AMOUNT OF INCOME TO APPROPRIATE FROM BOARD-DESIGNATED ASSETS, THE TRUSTEES CONSIDER THE NEED TO MAINTAIN UNRESTRICTED ASSETS TO MEET LIQUIDITY COVENANTS RELATED TO OUTSTANDING BONDS. ACCORDINGLY, THE BOARD OF TRUSTEES HAS SET THE INVESTMENT ALLOCATION TO ACHIEVE A NOMINAL RATE OF RETURN THAT WILL AT LEAST COVER INFLATION AND THE SPEND RATE WITH A PRUDENT LEVEL OF RISK. THE INVESTMENT ALLOCATION FOR THE BOARD-DESIGNATED PORTION OF THE ENDOWMENT IS SET TO ACHIEVE GREATER STABILITY IN THE VALUE OF INVESTMENTS. THE BOARD ALLOCATED 4% OF THE THREE YEAR AVERAGE VALUE OF DONOR-DESIGNATED ENDOWMENT BALANCES TO SUPPORT THE DESIGNATED PROGRAMS. ALL EARNINGS ON DONOR ENDOWMENTS ESTABLISHED TO PROVIDE GENERAL SUPPORT FOR THE LABORATORY AS APPROVED BY THE BOARD OF TRUSTEES WERE RETAINED IN THE ENDOWMENT. THE BOARD OF TRUSTEES WISHES TO INCREASE THE AMOUNT OF ENDOWMENT SUPPORT AVAILABLE IN THE FUTURE. LIABILITY FOR UNCERTAIN TAX POSITIONS UNDER FIN 48 (ASC 740) PART X, LINE 2 THE LABORATORY IS A NOT-FOR-PROFIT ORGANIZATION AS DESCRIBED IN SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE (THE CODE), AS AMENDED, AND IS GENERALLY EXEMPT FROM INCOME TAXES PURSUANT TO THE CODE. IN ACCORDANCE WITH GAAP, THE LABORATORY ASSESSES WHETHER THERE ARE UNCERTAIN TAX POSITIONS AND DETERMINED THERE WERE NO UNCERTAIN TAX POSITIONS THAT WOULD HAVE A MATERIAL EFFECT ON THE FINANCIAL STATEMENTS. OTHER REVENUE ON FINANCIAL STATEMENTS NOT ON RETURN PART XI, LINE 4B RECLASS OF FUNDRAISING EXPENSES (126,078) OTHER EXPENSES INCLUDED IN FINANCIAL STATEMENT NOT ON RETURN PART XII, LINE 2D RECLASS OF FUNDRAISING EXPENSES 126,078 OTHER LOSS ON FINANCIAL STATEMENTS NOT ON RETURN PART XI, LINE 2D UNREALIZED GAINS ON INTEREST RATE SWAPS 231,042 CHANGES IN ACTUARIAL ASSUMPTIONS 638,693 FAIR MARKET VALUE ADJUSTMENT ON LOANS 3,642,843 LOSS ON BOND REFUND (6,480,969) TOTAL (1,968,391) Europe (Including Iceland and Greenland) 1 Program Services RESEARCH 105773 Central America and the Caribbean Investments 19148490 East Asia and the Pacific Program Services EDUCATION 30295 1 1 19284558 19284558 false false false false true false X X X X X X X true CHRISTINA RUSSELL 206 BURWELL AVENUE HENDERSON NC 27536 FDN GRANT CONSULTING false 28803 28803 CA CT FL ME MA NY PA DISC DAY 97645 94345 3300 79575 DISC LUNCH 61815 58227 3588 35127 2 19650 19650 11376 179110 172222 6888 126078 126078 -119190 X true true X X X X X true true false false false false false true false EDISON T LIU MD 716254 0 0 0 70053 0 98173 0 23943 0 908423 0 0 0 CHARLES E HEWETT PHD 514721 0 29166 0 111922 0 227602 0 22607 0 906018 0 99500 0 MICHAEL HYDE 251111 0 20417 0 41811 0 25000 0 37513 0 375852 0 0 0 LINDA A JENSEN MS 262171 0 35000 0 15010 0 25000 0 32280 0 369461 0 0 0 KATHY L VANDEGRIFT 227734 0 33201 0 6231 0 21886 0 23286 0 312338 0 0 0 LEAH RAE B DONAHUE PHD 182427 0 17500 0 18378 0 18850 0 28502 0 265657 0 0 0 AUROBINDO NAIR PHD 262496 0 38117 0 12257 0 25000 0 30288 0 368158 0 0 0 ROBERT BRAUN PHD 302118 0 5833 0 26580 0 25000 0 11110 0 370641 0 0 0 MICHAEL WATERS 170373 0 33550 0 8192 0 19315 0 30178 0 261608 0 0 0 LINDA WATERMAN DVM 191434 0 38000 0 6809 0 16722 0 9041 0 262006 0 0 0 JANAN T EPPIG PHD 226593 0 0 0 0 0 22744 0 18746 0 268083 0 0 0 GARY A CHURCHILL PHD 207274 0 0 0 3629 0 21223 0 29312 0 261438 0 0 0 JOANNE RUH 268050 0 47000 0 5984 0 24468 0 1236 0 346738 0 0 0 BENEFITS PART I, LINE 1A TAX INDEMNIFICATION AND GROSS-UP PAYMENTS: THE JACKSON LABORATORY GROSSES UP THE AMOUNT ADDED TO WAGES FOR IMPUTED INSURANCE PREMIUMS FOR THE SENIOR MANAGEMENT GROUP TO COVER TAXES. THE LABORATORY ALSO GROSSES UP WAGES TO COVER THE TAX IMPACT OF GIFT CARDS AND OTHER AWARDS OR PRIZES TO EMPLOYEES SO THAT THE RECIPIENTS RECEIVE THE FULL VALUE OF THE GIFT OR AWARD. SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN PART I, LINE 4B THE LABORATORY MAINTAINS A DEFERRED COMPENSATION PLAN UNDER SECTION 457(F). THE PRESIDENT/CEO AND EXECUTIVE VICE PRESIDENT/COO PARTICIPATE IN A NON-QUALIFIED SUPPLEMENTAL RETIREMENT PLAN THAT PROVIDES FOR A PORTION OF THEIR COMPENSATION TO BE DEFERRED UNDER A SECTION 457 (F) PLAN. THE AMOUNT TAXABLE TO THE EXECUTIVE VICE PRESIDENT/COO UNDER THE PLAN DURING THE YEAR IS $86,710. NON-FIXED PAYMENTS PART I, LINE 7 THE TOTAL COMPENSATION PACKAGE OF CERTAIN OFFICERS, KEY EMPLOYEES, AND OTHER EMPLOYEES INCLUDES VARIABLE COMPENSATION AWARDED BASED ON PERFORMANCE. SEVERANCE PAYMENT PART I, LINE 4A THE JACKSON LABORATORY PAID SEVERANCE OF $20,790 TO THE CHIEF INFORMATION OFFICER DURING THE YEAR. A ABAG FINANCE AUTHORITY FOR NONPROFIT CORPORATIONS 943130123 00037CLX6 2007-09-12 35075000 FINANCE CONSTRUCTION & REFUND true false false B FINANCE AUTHORITY OF MAINE 042456011 2012-08-31 42460000 REFUND false false false C ABAG FINANCE AUTHORITY FOR NONPROFIT CORPORATIONS 943130123 00037CTH3 2012-10-24 66355769 FINANCE CONSTRUCTION & REFUND false false false A 1200000 33025000 35075000 0 1004292 0 456682 0 0 31597588 2016438 0 2009 true false true true B 0 0 42460000 0 0 42460000 0 0 0 0 0 0 2002 true false true true C 0 0 66355769 0 0 39067111 623401 0 0 26665257 0 0 2013 false true false true A false false true true true true 0.00386 0.00386 false false false false B false false false false true true 0.00072 0.00072 false false false false C false false true true true true 0.00907 0.00907 false false false false A false false false true false false 0 false 0 false false B false false false true true false 0 false 0 false false C false true false false false false 0 false 0 false false A true B true C true PART IV, LINE 2(C) 0 BOND ISSUE A - NO REBATE DUE, ARBITRAGE CALCULATION PERFORMED 9/11/12 BY AMTEC. BOND ISSUE B - NO REBATE DUE, ARBITRAGE CALCULATION PERFORMED 6/30/12 BY AMTEC. MADELEINE BRAUN KEY EMPLOYEE-ROBERT BRAUN 140946 EMPLOYMENT - FAMILY MEMBER false X 15 161444 FMV X IN-KIND CONTRIBUTIONS 6 1642 FMV false true false ORGANIZATION'S MISSION FORM 990, PART III, LINE 1 THE MISSION OF THE LABORATORY IS TO DISCOVER PRECISE GENOMIC SOLUTIONS FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. TO ACCOMPLISH THIS MISSION THE LABORATORY 1) CONDUCTS BASIC BIOMEDICAL RESEARCH TO INCREASE THE KNOWLEDGE OF DEVELOPMENT, GROWTH, REPRODUCTION, PHYSIOLOGICAL, AND GENETICALLY DETERMINED AILMENTS THROUGH RESEARCH WITH GENETICALLY DEFINED EXPERIMENTAL ANIMALS; 2) CONDUCTS TRANSLATIONAL BIOMEDICAL RESEARCH TO IDENTIFY THE GENOMIC BASIS FOR HUMAN DISEASE, PROMOTE THE ESTABLISHMENT OF MORE PRECISE, TARGETED THERAPIES, AND OFFER CUTTING EDGE GENOMIC DIAGNOSTICS TO THE MEDICAL COMMUNITY; 3) TRAINS AND EDUCATES SCIENTISTS, PHYSICIANS, AND OTHER PROFESSIONALS IN THESE AREAS; AND 4) PROMOTES SCIENTIFIC DISCOVERY THROUGH THE PROVISION OF MOUSE MODELS OF HUMAN DISEASE AND THE PROVISION OF RESEARCH AND CLINICAL SERVICES TO THE GLOBAL SCIENTIFIC AND MEDICAL COMMUNITY. IN 2012, THE LABORATORY ESTABLISHED JAX GENOMIC MEDICINE IN FARMINGTON, CT TO ACCELERATE THE TRANSLATION OF DISCOVERIES MADE IN BASIC RESEARCH TO TREATMENTS FOR HUMAN DISEASE. PROGRAM SERVICES FORM 990, PART III, LINE 4A-4C 4A. GENETIC RESOURCES THE JACKSON LABORATORY GENERATES AND MAINTAINS AN OPEN-SOURCE MOUSE GENOME DATABASE, THE WORLD'S LARGEST PUBLICALLY ACCESSIBLE INFORMATION SOURCE ABOUT THE LABORATORY MOUSE. IT IS AVAILABLE TO THE WORLDWIDE RESEARCH COMMUNITY, DRIVING DISCOVERY IN CANCER, DIABETES, OSTEOPOROSIS, ALZHEIMER'S DISEASE AND MANY OTHER AREAS CRITICAL TO HUMAN HEALTH. THIS DATABASE EXPERIENCES CLOSE TO 9 MILLION "HITS" PER WEEK. THE LABORATORY'S MOUSE REPOSITORY OFFERED A PORTFOLIO OF OVER 7,400 MOUSE LINES INCLUDING INBRED STRAINS, PANELS OF MICE FOR GENETIC MAPPING, MOLECULAR TOOL STRAINS, AND GENETICALLY ENGINEERED STRAINS. THESE INCLUDED A WIDE SELECTION OF STRAINS GENETICALLY ENGINEERED AS MOUSE MODELS OF HUMAN DISEASES, AMONG THEM CANCER, HEART DISEASE, ALZHEIMER'S DISEASE, ALS, DIABETES, PARKINSON'S DISEASE, SPINAL MUSCULAR ATROPHY, HUNTINGTON'S DISEASE AND VARIOUS AUTOIMMUNE DISEASES. THE JACKSON LABORATORY IS COLLABORATING WITH A COMPONENT OF THE NATIONAL CANCER INSTITUTE, THE UC DAVIS CANCER CENTER, AND OTHER CANCER CENTERS, TO IMPROVE THE SUCCESS RATE OF NEW CANCER DRUGS IN HUMAN CLINICAL TRIALS. UNDER THE COLLABORATION, A RANGE OF GENETICALLY ENGINEERED AND HUMAN TRANSPLANT MOUSE MODEL STUDIES WILL BE INTEGRATED WITH PATIENT TREATMENT CLINICAL TRIAL STUDIES UNDER A UNIFORM AND CONTROLLED TESTING MECHANISM. DATA RESULTING FROM THIS COMBINED APPROACH WILL HELP IDENTIFY MOLECULES (BIOMARKERS) THAT COULD PREDICT CONDITIONS UNDER WHICH CANDIDATE DRUGS WILL BE MOST EFFECTIVE. THE JACKSON LABORATORY HAS A NEW RARE AND ORPHAN DISEASE CENTER TO ADDRESS CONDITIONS THAT, WHILE INDIVIDUALLY RARE, COLLECTIVELY AFFECT ABOUT ONE IN 10 AMERICANS, ACCORDING TO THE NATIONAL ASSOCIATION FOR RARE DISORDERS. ABOUT 80 PERCENT OF RARE DISEASES ARE GENETIC IN ORIGIN, ABOUT HALF AFFECT CHILDREN, MANY ARE FATAL, AND VERY FEW HAVE CURES RARE CONDITIONS ARE OFTEN DESCRIBED AS "ORPHAN" BECAUSE THEY RECEIVE RELATIVELY LITTLE ATTENTION AND INVESTMENT FROM PHARMACEUTICAL COMPANIES. TREATMENTS FOR RARE DISEASES OFFER LOWER POTENTIAL FINANCIAL RETURN ON INVESTMENT COMPARED TO DRUGS FOR MORE COMMON, HIGH-VISIBILITY CONDITIONS SUCH AS CANCER AND DIABETES. TO ADDRESS THIS MAJOR HEALTH ISSUE, THE NONPROFIT JACKSON LABORATORY LAUNCHED THE NEW RARE AND ORPHAN DISEASE CENTER TO CONSOLIDATE ITS RESEARCH INTO THE GENETIC BASIS OF SOME OF THESE CONDITIONS AND TO APPLY ITS SPECIALIZED RESEARCH RESOURCES TO HELP SCIENTISTS AROUND THE WORLD IN THEIR SEARCH FOR NEW TREATMENTS FOR UNCOMMON CONDITIONS. 4B. RESEARCH JACKSON LABORATORY RESEARCHERS LED BY ASSOCIATE PROFESSOR ZHONG-WEI ZHANG, PH.D., PROVIDED DIRECT EVIDENCE THAT A SPECIFIC NEUROTRANSMITTER RECEPTOR IS VITAL TO THE PROCESS OF PRUNING SYNAPSES IN THE BRAINS OF NEWBORN MAMMALS. FAULTY PRUNING AT THIS EARLY DEVELOPMENTAL STAGE IS IMPLICATED IN AUTISM-SPECTRUM DISORDERS AND SCHIZOPHRENIA. JACKSON LABORATORY RESEARCHERS FOUND A GENE THAT CONTROLS MULTIPLE PROCESSES ESSENTIAL TO BUILDING A VIABLE MAMMALIAN EGG, MAKING IT A MASTER REGULATOR OF EGG DEVELOPMENT. THE RESEARCH TEAM, LED BY PROFESSOR JOHN EPPIG, PH.D., SHOWED THAT A GENE THEY NAMED MARF1 IN MICE DIRECTS KEY PROCESSES NEEDED TO PRODUCE EGGS CAPABLE OF BEING FERTILIZED AND DEVELOPING INTO HEALTHY BABIES. DEFECTS IN THE GENE RESULTED IN A CASCADE OF ABNORMALITIES, RESULTING IN DEFECTIVE EGG PRODUCTION AND FEMALE INFERTILITY. JACKSON LABORATORY RESEARCHERS DEMONSTRATED THAT A SINGLE, TARGETED X-RAY TREATMENT OF AN INDIVIDUAL EYE IN YOUNG, GLAUCOMA-PRONE MICE PROVIDED THAT EYE WITH APPARENTLY LIFE-LONG AND TYPICALLY COMPLETE PROTECTION FROM GLAUCOMA. IN RESEARCH PUBLISHED IN THE JOURNAL OF CLINICAL INVESTIGATION, GARETH HOWELL, PH.D., SIMON JOHN, PH.D., (PROFESSOR AND HOWARD HUGHES MEDICAL INVESTIGATOR) AND COLLEAGUES ALSO USED SOPHISTICATED GENOMICS METHODS TO UNCOVER SOME OF THE VERY FIRST PATHWAYS TO CHANGE DURING GLAUCOMA IN THESE MICE. THE FIRST PATHWAY THEY DETECTED TO CHANGE SUGGESTS A CRITICAL MECHANISM THAT COULD BE RESPONSIBLE FOR THE EARLIEST DAMAGE THAT GLAUCOMA INFLICTS ON THE OPTIC NERVE. A JACKSON LABORATORY RESEARCH TEAM LED BY PROFESSOR AND HOWARD HUGHES MEDICAL INVESTIGATOR SUSAN ACKERMAN, PH.D., DISCOVERED A DEFECT IN THE RNA SPLICING PROCESS IN NEURONS THAT MAY CONTRIBUTE TO NEUROLOGICAL DISEASE. THE RESEARCHERS FOUND THAT A MUTATION IN JUST ONE OF THE MANY COPIES OF A GENE KNOWN AS U2 SNRNAS, WHICH IS INVOLVED IN THE INTRICATE PROCESSING OF PROTEIN-ENCODING RNAS, CAUSES NEURODEGENERATION. MANY SO-CALLED NON-CODING RNAS-THOSE THAT DON'T DIRECTLY ENCODE PROTEINS-ARE FOUND IN MULTIPLE COPIES IN THE GENOME. FOR THE FIRST TIME, IT WAS SHOWN THAT A MUTATION IN ONE COPY CAN LEAD TO DISEASE. THE JACKSON LABORATORY CREATED A NEW INSTITUTE FOR GENOMICS-BASED PERSONALIZED MEDICINE IN CONNECTICUT. JAX GENOMIC MEDICINE, LOCATED ON THE CAMPUS OF THE UNIVERSITY OF CONNECTICUT HEALTH CENTER, WILL FOCUS ON MEDICAL APPLICATIONS OF GENOMICS AND PERSONALIZED MEDICINE WITH ACADEMIC AND CLINICAL PARTNERS IN CONNECTICUT AND AROUND THE WORLD. 4C. TRAINING THE JACKSON LABORATORY PROVIDED 20 COURSES, CONFERENCES, SEMINARS AND WORKSHOP EVENTS. THESE UNIQUE EDUCATIONAL OPPORTUNITIES ATTRACTED 595 PARTICIPANTS FROM THE NATIONAL AND INTERNATIONAL RESEARCH COMMUNITIES, AFFORDING THEM WITH OPPORTUNITIES TO TRADE INSIGHTS WITH 308 FACULTY MEMBERS. THE JACKSON LABORATORY HAS OFFERED SCHOOL-YEAR INTERNSHIPS TO HIGH SCHOOL STUDENTS FROM REGIONAL HIGH SCHOOLS SINCE 1993. THIS PROGRAM ATTRACTED EIGHT STUDENTS. A HANDS-ON PROGRAM FOR SCIENCE TEACHERS ATTRACTED FIVE PARTICIPANTS. THIS INNOVATIVE TEACHER SABBATICAL INTERNSHIP PROGRAM PROVIDES MATHEMATICS AND SCIENCE TEACHERS IN MAINE PUBLIC SECONDARY SCHOOLS HANDS-ON RESEARCH EXPERIENCE DURING A SEMESTER AT THE JACKSON LABORATORY. THE JACKSON LABORATORY'S HISTORIC SUMMER STUDENT PROFRAM HAD 39 TALENTED PARTICIPANTS. THE NATIONALLY RENOWNED PROGRAM PROVIDES HIGH SCHOOL AND COLLEGE STUDENTS WITH AN OPPORTUNITY TO CONDUCT INDEPENDENT RESEARCH UNDER THE GUIDANCE OF STAFF SCIENTISTS. MORE THAN 2,200 STUDENTS, INCLUDING THREE NOBEL LAUREATES, HAVE PARTICIPATED IN THE PROGRAM. MOST ALUMNI GO ON TO CAREERS IN MEDICINE OR RESEARCH. FORM 990 REVIEW PROCESS FORM 990, PART VI, SECTION B, QUESTION 11A THE AUDIT COMMITTEE OF THE JACKSON LABORATORY'S BOARD OF TRUSTEES REVIEWS A DRAFT COPY OF THE IRS FORM 990 BEFORE IT IS PROVIDED TO THE BOARD OF TRUSTEES. AFTER REVIEW, THE IRS FORM 990 IS FINALIZED AND FILED. CONFLICT OF INTEREST POLICY FORM 990, PART VI, SECTION B, QUESTION 12C THE JACKSON LABORATORY PROVIDES ALL OFFICERS, BOARD MEMBERS AND KEY EMPLOYEES WITH A CONFLICT OF INTEREST, CODE OF ETHICS AND DISCLOSURE FORMS AS WELL AS THE DISTRIBUTION OF ALL POLICIES REGARDING THE CONFLICT OF INTERESTS AND CODE OF ETHICS, THIS PROCESS IS DONE ANNUALLY. THE DISCLOSURE AND COMPLIANCE ATTESTATIONS ARE RETURNED TO THE OFFICE OF TRUSTEE RELATIONS, WHERE THEY ARE RECORDED AND TALLIED FOR COMPLETENESS. DISCLOSURES, AS WELL AS ANY FOLLOW UP QUESTIONS, ARE ROUTED THROUGH THE IN-HOUSE COUNSEL, AND IF NECESSARY THE AUDIT COMMITTEE. COMPENSATION POLICY FORM 990, PART VI, SECTION B, QUESTION 15B THE COMPENSATION AND HUMAN RESOUCES COMMMITTEE OF THE BOARD OF TRUSTEES SETS COMPENSATION AND BENEFITS FOR THE CHIEF EXECUTIVE OFFICER, EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER, THE VICE PRESIDENT OF RESEARCH, THE VICE PRESIDENT OF EXTERNAL AFFAIRS AND STRATEGIC PARTNERSHIPS, THE CHIEF FINANCIAL OFFICER AND EQUIVALENT POSITIONS AS WELL AS ANY OTHER EMPLOYEES OF THE LABORATORY WHO WOULD BE CONSIDERED 'INSIDERS' OR 'DISQUALIFIED PERSONS' WITHIN THE MEANING OF THE INTERMEDIATE SANCTIONS RULES UNDER THE INTERNAL REVENUE CODE. MEMBERS OF THE COMMITTEEE ARE INDEPENDENT TRUSTEES SELECTED BY THE CHAIR OF THE BOARD OF TRUSTEES. THE COMMITTEE IS GUIDED BY MARKET DATA OF COMPENSATION PACKAGES FOR SIMILAR POSITIONS IN COMPARABLE ORGANIZATIONS. MARKET DATA IS PREPARED FOR THE COMMITTEE BY AN EXTERNAL EXECUTIVE COMPENSATION FIRM WHICH CONSIDERS COMPENSATION INFORMATION REPORTED IN FORM 990'S OF COMPARABLE ORGANIZATIONS AND THE RESULTS OF RECOGNIZED COMPENSATION SURVEYS. THE SENIOR DIRECTOR OF HUMAN RESOURCES IS AVAILABLE TO THE COMMITTEE TO PROVIDE ANY OTHER DATA NEEDED. THE CEO MEETS WITH THE COMMITTEE AT LEAST ANNUALLY TO PROVIDE THE COMMITTEE MEMBERS WITH ANNUAL PERFORMANCE REVIEWS OF HIS REPORTS. THE COMMITTEE'S REVIEW PROCESS AND RESULTS ARE DOCUMENTED IN MINUTES OF THE MEETINGS. PUBLIC DISCLOSURE FORM 990, PART VI, SECTION C, QUESTION 19 THE ORGANIZATION'S FORM 990 IS AVAILABLE ON WWW.GUIDESTAR.ORG AND ON THE ORGANIZATION'S PUBLIC WEBSITE JAX.ORG. OTHER CHANGES IN NET ASSETS FORM 990, PART XI, LINE 9 UNREALIZED GAINS ON INTEREST RATE SWAPS 231,042 CHANGES IN ACTUARIAL ASSUMPTIONS 638,693 FAIR MARKET VALUE ADJUSTMENT ON LOANS 3,642,843 LOSS ON BOND REFUND (6,480,969) TOTAL (1,968,391) SECURED MORTGAGES AND NOTES PAYABLE FORM 990, PART X, LINE 23 REPAYMENT TERMS THE CT INNOVATIONS LOANS WILL BE FORGIVEN IF AND WHEN THE LABORATORY MEETS AN EMPLOYMENT GOAL OF AT LEAST 300 EMPLOYEES LOCATED IN CONNECTICUT FOR A PERIOD OF SIX MONTHS, INCLUDING A MINIMUM OF 90 SENIOR SCIENTISTS. IN ADDITION, THE AVERAGE WAGE FOR SUCH EMPLOYEES MUST EXCEED A MINIMUM TARGET LEVEL.